Bausch Health And Alfasigma Announce Resolution Of XIFAXAN(R) Intellectual Property Litigation

Salix Will Maintain Market Exclusivity for XIFAXAN® (rifaximin) 550 mg Tablets Until 20281 LAVAL, Quebec, May 6, 2020 -- (Healthcare Sales & Marketing Network) -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "... Biopharmaceuticals, Litigation, Licensing Bausch Health Companies, Salix Pharmaceuticals, Alfasigma , Sandoz
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news